TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.

It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
A Black woman in her late 30s is brushing back her young daughter's hair into a ponytail. The woman is wearing a flowered head scarf and has a calm expression while her daughter smiles. Not actual patients, but actual stories.

UNDERSTANDING METASTATIC TRIPLE-NEGATIVE BREAST CANCER

How mTNBC is different from other types of breast cancer

Different types of breast cancer are classified by whether or not the cancer cells have certain proteins called receptors. Cancer cells may have receptors for 2 types of hormones (estrogen or progesterone) or another receptor called HER2. If cancer cells have (or are positive for) these certain types of receptors, they can be treated with therapies that target those receptors or that cause the body to make fewer hormones.

But mTNBC cells are negative for estrogen receptors, progesterone receptors, and HER2, which means they tested negative for those 3 receptors, hence the name triple-negative breast cancer. Without these receptors, treatment for mTNBC is more limited than other types of breast cancer and may require a different approach.

TRODELVY is the only metastatic TNBC treatment of its kind

Unlike some other therapies, TRODELVY does not need cancer cells to have estrogen receptors, progesterone receptors, or HER2 in order to work, which is why it is an option for people with mTNBC. Rather, TRODELVY is designed to seek out a different protein that may be present on breast cancer cells, including those found in mTNBC. See how TRODELVY is thought to work.

What is Trodelvy?

TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.

A young white woman with a shaved head is taking a selfie with her friend, a young Black woman with short hair. The women are hugging and are both smiling softly at the camera. Not an actual patient.
icon-quote-left I heard about TRODELVY online and brought it up with my healthcare team. After going over the risks and benefits, we decided together that it was a good fit. icon-quote-right
- Deltra, a woman taking TRODELVY

More About TNBC

  • The majority of TNBC cases are diagnosed in women 51-60 years old
  • When women under 40 are diagnosed with breast cancer, it is more likely to be TNBC than if they are diagnosed over 40
  • TNBC more commonly affects African American and Hispanic women
  • Breast cancers associated with a BRCA* mutation (either BRCA-1 or BRCA-2) are often, but not always, triple negative

TNBC Community Support

Here are some additional resources that may be helpful to patients, families, and care partners dealing with breast cancer. The following resources are not controlled or owned by Gilead, and Gilead is not responsible for their content.

Breastcancer.org: A complete resource for patients with breast cancer.

Living Beyond Breast Cancer®: Information, community, and support for people whose lives have been impacted by breast cancer.

METAvivor: Dedicated to increasing awareness of advanced breast cancer and equity in research and patient support.

Share Cancer Support: A supportive community of women affected by breast or ovarian cancer.

Sharsheret®: A Jewish breast cancer organization that helps women and their families face breast cancer.

Sisters Network® Inc: Committed to increasing local and national attention to the devastating impact that breast cancer has in the African American community.

Triple Negative Breast Cancer Foundation®: Dedicated to raising awareness of triple-negative breast cancer.

Young Survival Coalition®: Dedicated to the critical issues unique to young women who are diagnosed with breast cancer.

What is TRODELVY?

TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.

It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.

Important Safety Information

TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:
  • Low white blood cell count (neutropenia) which is common and can sometimes be severe and lead to infections that can be life-threatening or cause death. Your healthcare provider should check your blood cell counts during treatment. If your white blood cell count is too low, your healthcare provider may need to lower your dose, give you a medicine to help prevent low blood cell count with future doses of TRODELVY, or in some cases may stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
  • Severe diarrhea. Diarrhea is common and can be severe. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid (dehydration), your healthcare provider may need to give you fluids and electrolytes to replace body salts. If diarrhea happens later in your treatment, your healthcare provider may check you to see if it may be caused by an infection. Your healthcare provider may decrease your dose or stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
    • Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.

Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).

Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.

Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:

  • have been told that you carry a gene for UGT1A1*28, which can increase your risk of getting side effects with TRODELVY, especially low white blood cell counts, with or without a fever, and low red blood cell counts.
  • have liver problems.
  • are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY. TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.
    • Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time.
    • Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.
    • Tell your healthcare provider right away if you or your partner become pregnant during treatment with TRODELVY.
  • are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.

The most common side effects of TRODELVY include feeling tired or weak, hair loss, decreased red blood cell count, constipation, decreased appetite, rash, and stomach-area (abdominal) pain or discomfort.

These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please click to see Important Facts about TRODELVY, including Important Warning.